Dr. Ingrid Mayer MD Medical Oncologist

Dr. Ingrid Mayer is a medical oncologist in Nashville, Tennessee. She is affiliated with multiple hospitals in the area, including Tennessee Valley Healthcare System and Vanderbilt Hospital and Clinics. She received her medical degree from Paulista School of Medicine and has been in practice for 21 years. Dr. Mayer accepts several types of health insurance, listed below. She is one of 13 doctors at Tennessee Valley Healthcare System and one of 29 at Vanderbilt Hospital and Clinics who specialize in Medical Oncology. She also speaks multiple languages, including French and Arabic.

Are you Dr. Ingrid Mayer? Claim your profile to make edits or add details. Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: General Oncology

Hospital Affiliation

Tennessee Valley Healthcare System

Vanderbilt Hospital and Clinics
Ranked #28 in Cancer

Education & Medical Training

University of Illinois College of Medicine at Chicago
Residency, Internal Medicine, 1994 - 1998

University of Illinois College of Medicine at Chicago
Fellowship, Hematology/Oncology, 1998 - 2001

Paulista School of Medicine
Class of 1993


Other Training, Clinical Investigation, 2004 - 2006

Certifications & Licensure

American Board of Family Medicine
Certified in Family Medicine

American Board of Family Medicine
Certified in Sports Medicine

AZ State Medical License
Active through 2014

Awards, Honors & Recognition

Meaningful Use Stage 1 Certification, Centers for Medicare & Medicaid Services
2012

Five Star Awards in the Excellence in Healthcare Awards
2010

Alpha Omega Alpha Honor Medical Society (AOA)
1996

Department of Medicine House Staff Award, PGY-II of the Year
1995

Publications & Presentations

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer
Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC 2013 5 1

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor2-overexpressing breast cancer: TBCRC 006
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC 2013 5 1

Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report
Iams W, Beckermann KE, Neff AT, Mayer IA, Abramson VG 2013 1 1

See all 44 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • BCBS Blue Card PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Empire BCBS HMO
  • Empire BCBS PPO
  • First Health PPO
  • GHI PPO
  • Great West PPO
  • HIP of New York - Select PPO
  • Humana ChoiceCare Network PPO
  • MagnaCare PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • MVP Healthcare PPO
  • Oxford Health Freedom
  • Oxford Health Liberty
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
Find More Doctors
Doctor Finder

Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Browse Doctors by

Specialty

Location

Search all Doctors

Profiles by Doximity

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.